4/11
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/8
08:15 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Medium
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
3/14
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/13
04:05 pm
acad
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Medium
Report
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
3/8
02:05 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/7
12:32 pm
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $20.00 price target on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $20.00 price target on the stock.
3/5
09:18 am
acad
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med [Yahoo! Finance]
Low
Report
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med [Yahoo! Finance]
3/5
09:05 am
acad
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
Low
Report
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
3/3
09:05 am
acad
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
Medium
Report
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
2/28
11:04 pm
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/28
07:07 pm
acad
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Medium
Report
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/27
04:32 pm
acad
Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference [Yahoo! Finance]
2/27
04:05 pm
acad
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
Low
Report
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
2/27
11:43 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
Medium
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
2/27
09:22 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
2/27
08:08 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
2/26
04:36 pm
acad
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview [Yahoo! Finance]
2/26
04:05 pm
acad
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
Low
Report
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
2/16
02:24 pm
acad
https://seekingalpha.com/article/4758871-stoke-therapeutics-stock-pivotal-moment-for-this-rna-pioneer [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4758871-stoke-therapeutics-stock-pivotal-moment-for-this-rna-pioneer [Seeking Alpha]
2/14
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/12
04:46 pm
acad
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 [Yahoo! Finance]
Medium
Report
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 [Yahoo! Finance]
2/12
04:05 pm
acad
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Medium
Report
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
2/11
07:26 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "hold" rating and a $22.00 price target on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "hold" rating and a $22.00 price target on the stock.
1/17
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)